Abbott Bets $410 Mil. On Evalve's Transcatheter Valve Repair Technology
This article was originally published in The Gray Sheet
Executive Summary
Abbott is betting big on Evalve's MitraClip minimally invasive mitral valve repair system
You may also be interested in...
Abbott's MitraClip Climbs EVEREST II: What Patients Are On The Other Side?
Abbott's minimally invasive MitraClip device has the potential to control up to a $400 million worldwide market in the mitral valve repair space, analysts say, but questions remain on how the largely positive pivotal data reported last week will translate into market adoption
Abbott's MitraClip Climbs EVEREST II: What Patients Are On The Other Side?
Abbott's minimally invasive MitraClip device has the potential to control up to a $400 million worldwide market in the mitral valve repair space, analysts say, but questions remain on how the largely positive pivotal data reported last week will translate into market adoption
ACC 2010: Transcatheter Mitral Valve Repair Data Among Expected Highlights
A substantial 2009 acquisition by Abbott could be validated and the prospects for Boston Scientific's future drug-eluting stent portfolio weighed from data set to be presented later this month at the American College of Cardiology annual conference